Phase 3 trial of vercirnon doesn’t meet endpoint

 A Phase 3 study of vercirnon, an investigational drug for patients with Crohn’s disease, has failed to meet its primary endpoint of improvement in clinical response, and a secondary endpoint of clinical remission, GlaxoSmithKline Plc said.